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Abstract
Background: Neither HBV DNA nor HBsAg positivity at birth is an accurate marker for HBV infection of infants. No
data is available for continuous changes of HBV markers in newborns to HBsAg(+) mothers. This prospective,
multi-centers study aims at observing the dynamic changes of HBV markers and exploring an early diagnostic
marker for mother-infant infection.
Methods: One hundred forty-eight HBsAg(+) mothers and their newborns were enrolled after mothers signed the
informed consent forms. Those infants were received combination immunoprophylaxis (hepatitis B immunoglobulin
[HBIG] and hepatitis B vaccine) at birth, and then followed up to 12 months. Venous blood of the infants (0, 1, 7,
and 12 months of age) was collected to test for HBV DNA and HBV markers.
Results: Of the 148 infants enrolled in our study, 41 and 24 infants were detected as HBsAg(+) and HBV DNA(+) at
birth, respectively. Nine were diagnosed with HBV infection after 7 mo follow-up. Dynamic observation of the HBV
markers showed that HBV DNA and HBsAg decreased gradually and eventually sero-converted to negativity in the
non-infected infants, whereas in the infected infants, HBV DNA and HBsAg were persistently positive, or higher at
the end of follow-up. At 1 mo, the infants with anti-HBs(+), despite positivity for HBsAg or HBV DNA at birth, were
resolved after 12 mo follow-up, whereas all the nine infants with anti-HBs(−) were diagnosed with HBV infection.
Anti-HBs(−) at 1 mo showed a higher positive likelihood ratio for HBV mother-infant infection than HBV DNA and/or
HBsAg at birth.
Conclusions: Negativity for anti-HBs at 1 mo can be considered as a sensitive and early diagnostic indictor for HBV
infection in the infants with positive HBV DNA and HBsAg at birth, especially for those infants with low levels of
HBV DNA load and HBsAg titer.
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Background
With the hepatitis B vaccination program implementation
in China, hepatitis B surface antigen (HBsAg) carrier rate
reduced from 9.75% in 1992 to 7.18% in 2006 [1]. While
considering the large population of China, there are still
mounts of newborns of HBsAg(+) mothers at high risk
for hepatitis B virus (HBV) infection. Moreover, HBV in-
fection of newborns is likely to cause chronic disease and
serious subsequent complications.
Although combined immunoprophylaxis provides a
high protective efficacy, it does not completely eradicate
HBV transmission. HBV intrauterine infection is one of
the main reasons for the failure of combined immuno-
prophylaxis, which represents 5%–10% of infants’ infec-
tion born to HBsAg(+) mothers [2-5].
Mother-to-infant transmission of HBV remains to be
intensively studied. Currently, there is still no recognized
diagnostic standard for HBV infection of infants. Early
studies recommended that HBV DNA positivity in the
cord blood can be used as a criterion for HBV mother-
infant infection; however, the cord blood can be easily
contaminated by the maternal blood. Zhu and Zhuang
et al. provided evidences that testing of venous blood for
HBsAg or HBV DNA of infants at birth was more accur-
ate than cord blood for diagnosis of HBV infection [4,6].
Controversial data showed that about 10%-23% of infants
from HBsAg(+) mothers with combined immunoprophy-
laxis displayed HBV DNA(+) or HBsAg(+) at birth, the
positive rate gradually reduced during follow-up [4,7],
therefore Zhu et al. proposed that infants whose HBV
DNA or HBsAg remained positive for more than 3 months
can be identified as having been infected [4]. Recently,
new evidences recommended that infants who were sero-
positive for HBsAg and HBV DNA at 7 months could be
identified as having acquired HBV infection [6-9]. Those
data deepened our understanding of HBV infection of in-
fants, development of a sensitive and early diagnostic in-
dictor is needed for HBV infection of infants.
Other than positive rate, HBV markers titer and HBV
DNA load also changes with ages. For the reason of pla-
centa transmission, HBsAg was detected positive in in-
fants even the non-infected ones at birth [8]. Jiang et al.
showed that HBV DNA load, hepatitis B e antigen
(HBeAg) and HBsAg titers at 12 months in HBV infected
infants significantly increased as compared to birth [8].
According to our knowledge, no data reported the
changes of HBsAg titer and HBV DNA load in those
non-infected infants and the comparison of the HBV
markers modes and quantification between infected and
non-infected infants. From the aspect of quantification of
HBV markers assay, most lower limit of HBV DNA detec-
tion as shown in the literatures was about 500 IU/ml or
higher [2,7]. However, infants with HBV DNA below
500 IU/ml at birth, which detected negative with traditional
detection system, were also at risk of infection [10]. With
the development of more sensitive detection system, HBV
DNA detection lower limit can be as low as 12 IU/ml as
used in this study.
In this prospective, multi-centers study, kinetics of
viral markers titer and HBV DNA load were investigated
with more accurate assay methods, in infants treated
with combined immunoprophylaxis by follow-up as long
as 12 months, HBV markers modes and quantification
were also compared, try to identify a sensitive and early
indicator for HBV infection of infants.
Methods
Subjects
From November 2009 to August 2011, 148 pregnant
women who were screened HBsAg positive during their
prenatal care were recruited from 16 hospitals in Shaanxi
Province, China. The inclusion criteria for participants
were as follows: 20–40 years old, positivity for serum
HBsAg, negative for anti-HBs. All participants in this
study signed written informed consent forms for the par-
ticipation of their infants upon birth. The study protocol
was approved by the ethics committee of the First
Affiliated Hospital of Xi’an Jiaotong University. Data files
were kept locked to ensure confidentiality of respondents.
Data and samples collection
After childbirth, data were collected from the recruited
women’s medical records, which include fully medical
care information before and after delivery.
Maternal venous blood was collected before delivery and
neonatal venous blood was taken prior to combined immu-
noprophylaxis. The infants were consecutively followed up
at 0, 1, 7, and 12 months of age (blood was taken before
hepatitis B vaccine injection). Serum was separated for
HBV DNA load tests and measurement of HBV serum
markers titer (HBsAg, anti-HBs, HBeAg, and hepatitis B
core antibody [anti-HBc]).
Immunization schedule
Combined immunoprophylaxis scheduled as following,
HBIG (200 IU; Hualan Biological Engineering Inc.,
Henan, China) and the first dose of the hepatitis B
vaccine (Shenzhen Kangtai Biological Products Co. Ltd.,
Guangdong, China) at different injection sites within 12 h
postpartum, followed by the other 2 doses of the hepatitis
B vaccine at the ages of 1 and 6 months, respectively.
Laboratory methods
HBV serum markers (HBsAg, anti-HBs, HBeAg, and
anti-HBc) were quantified by the Abbott ARCHITECT
HBsAg, anti-HBs, HBeAg, and anti-HBc assays, respect-
ively (lower limits of the dynamic range: 0.05 IU/mL,
10.00 mIU/mL, 1.00 s/co, and 1.00 s/co, respectively;
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Abbott Laboratories, Chicago, USA). The HBV DNA
load was measured by a real-time PCR-based Roche
COBAS AmpliPrep/COBAS TaqMan HBV test (lower
limit of the dynamic range: 12 IU/mL; Roche Molecular
Systems). Liver function tests were performed with an
automated bioanalyzer (Olympus AU5400, Japan). Geno-
types were determined by an in-house nested PCR assay,
as described in the previous study [11].
Statistical analysis
EpiData 3.0 was used to establish the clinical database.
Data were double-checked for transcription errors, and
were then analyzed statistically with SPSS 13.0. Descrip-
tive analysis (calculations of averages, frequencies, pro-
portions, or rates) was conducted. The chi-square for
R × C table test was used for comparison between more
than 2 groups. Mixed ANOVA was used to compare
trends and changes between 2 groups. Quantitative data
were analyzed with Shapiro-Wilk test and Levene statis-
tic for normality and homogeneity of variance, respect-
ively. According to situation, correlations of two
quantitative groups were analyzed with Pearson or
Spearman correlation test. The positive likelihood ratio
was used for assessing the value of a diagnostic indicator
and calculated as: positive likelihood ratio = sensitivity/
(1-specificity).
Results
Profiles of mothers and newborns
Among the 148 HBsAg(+) mothers enrolled, 41 (27.7%)
were HBeAg(+), 38 (25.7%) had high levels of HBV
DNA load (more than 105 IU/mL), 129 (87.2%) showed
a normal alanine aminotransferase (ALT) level at deliv-
ery, and 139 (93.9%) were infected with HBV genotype C
(Table 1).
Among 148 infants, 70 infants (47.3%) were female, 78
(52.7%) were male. The positive rates of HBV DNA,
HBsAg, HBeAg, and anti-HBc in the newborns at birth
were 16.2%, 27.7%, 23.6%, and 100%, respectively. All
newborns were negative for anti-HBs (i.e., anti-HBs titer
was less than 10 mIU/mL) at birth (Table 1).
Correlation of HBsAg and HBV DNA between mothers
and newborns
Of the 148 infants born to HBsAg(+) mothers, 41 were
detected HBsAg positive at birth. To discover the rela-
tionship of HBsAg between mothers and infants, HBsAg
titer of those 41 mother-infant pairs were analyzed, no
correlation was found between the pairs (r = 0.188,
p = 0.239). However, when the mothers were stratified
into high, intermediate and low levels of HBsAg titer, as
shown in Figure 1A, infants from high HBsAg level
group were at higher risk of HBsAg positive rate at birth
(p < 0.001).
Attributed to a sensitive HBV DNA detection system,
24 infants were detected positive (> 12 IU/mL), which
was much higher than data reported by literature [8,10].
Similar with HBsAg, no correlation was found between
the double HBV DNA positive mother-infant pairs (r =
0.370, p = 0.076). Further analysis of stratified mothers
with HBV DNA level showed similarity to HBsAg, as in-
dicated in Figure 1B, high level HBV DNA mother-
groups confer greater risk to infants HBV DNA positive
at birth (p < 0.001).
Positive rate of HBV markers and HBV DNA in infants
Next, we investigated changes in the positive rates of
HBV markers and HBV DNA over the first year of the
infants’ lives. The rates of HBV DNA(+), HBsAg(+),
HBeAg(+), and anti-HBc(+) in infants reduced gradually
during the follow-up (χ2: 9.67, 592.01, 36.83, and 190.7,
respectively; P = 0.022, <0.001, <0.001, and <0.001, re-
spectively). Although anti-HBs is a placenta- transmit-
table antibody, because all the mothers enrolled were
anti-HBs negative, it was not surprising that all the in-
fants were negative for anti-HBs at birth. Attributed to
the combined immunoprophylaxis, 93.9% (139/148),
89.9% (133/148) and 87.8% (130/148) of the infants were
detected protective anti-HBs at 1 month, 7 months and
12 months, respectively (Figure 2). Nine (6.1%) infants
who were detected anti-HBs(−) at 1 month were anti-HBs
(−) and HBV DNA(+) at both 7 months and 12 months.
It was the nine infants that were diagnosed with HBV in-
fection by follow-up. The failure rate of combined immu-
noprophylaxis in this study was comparable with
literature (5%-10% vs. 6.1%) [2-5].
Among mothers of the 9 infected infants, 6 of them
had high HBV DNA load (>105 IU/mL), and all of them
had high levels of HBsAg (>104 IU/mL). Six mothers
Table 1 Characteristics of mothers and infants enrolled in
the study
Mothers (Total mothers 148)
Age, years, Mean ± SD (range) 25.9 ± 3.8 (20–38)
Elevated ALT levels, N (%)* 19 (12.8%)
ALT, Mean ± SD, (range), U/L 25.5 ± 30.1 (4.0–249.0)
AST, Mean ± SD, (range), U/L 30.6 ± 34.4 (11.1–343.0)
HBeAg(+), N (%) 41 (27.7%)
HBV DNA more than 105 IU/mL, N (%) 38 (25.7%)
Genotype C, N (%) 139 (93.9%)
Neonates (Total neonates 148)
Female: Male 70:78
HBsAg(+) at birth, N (%) 41 (27.7%)
HBeAg(+) at birth, N (%) 35 (23.6%)
HBV DNA(+) at birth, N (%) 24 (16.2%)
* Elevated ALT level was defined as the value of ALT level is upper 40 U/L.
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were HBeAg(+), and 3 were HBeAg(−) (Table 2). All 9
mothers were positive for HBV genotype C, the domin-
ant genotype in China as shown in our previous study
[12].
Comparison of the dynamic changes in HBV markers titer
and HBV DNA load between infected and uninfected
infants
As showed before, 9 infants with continuous HBV DNA(+)
and HBsAg(+) were diagnosed with HBV infection. Dy-
namic tendency in HBV DNA load, HBsAg, HBeAg, anti-
HBc, and anti-HBs titers were significantly different be-
tween 9 infected infants and 139 uninfected infants (F =
2.13 × 1010, P < 0.001; F = 87.78, P < 0.001; F = 2.59 × 107, P
< 0.001; F = 6.73, P < 0.001; and F = 2.82, P = 0.047, respect-
ively; Figure 3). HBV DNA load, HBsAg and HBeAg titers
of the 9 HBV infected infants increased gradually, while
139 uninfected infants went opposite way. Nine infected
infants presented anti-HBs(−) even under consecutive de-
tection, whereas the titers in the 139 non-infected infants
increased.
At birth, 24 newborns were positive for HBV DNA, 41
newborns were positive for HBsAg. 17 newborns were
double positive for HBV DNA and HBsAg. Although
evidences exists that HBV DNA and HBsAg can be diag-
nostic indictors for HBV infection of infants, the specifi-
city and sensitivity of those two markers remains to be
studied. Ours results showed that high levels of HBV
DNA load at birth (more than 105 IU/mL) detected in 5
infants was a robust predictive marker for HBV infection
at 12 months. Among those 19 infants with low levels of
HBV DNA (less than 105 IU/mL), 15 infants who were
anti-HBs detected positive at 1 month were negative for
HBV DNA and HBsAg at the age of 12 months, 4 in-
fants were persistently positive for HBV DNA and
HBsAg and negative for anti-HBs (Figure 4A).
As we mentioned before, conventional quantification
assay detects HBV DNA lower limit at about 500 IU/ml,
however, as shown in Figure 4, 2 infants with HBV DNA
load less than 500 IU/ml at birth were diagnosed with
HBV infection at 12 months, which call for a sensitive
HBV DNA detection system. In this study, the lower
limit of HBV DNA detection was as low as 12 IU/ml,
100% HBV infected infants at 12 months were detected
HBV DNA positive at birth.
As shown in Figure 4, 4 infants with high levels of
HBsAg titer (more than 250 IU/mL) at birth, persistently
positive for HBV DNA and HBsAg, were diagnosed with
Figure 1 Correlation of HBsAg and HBV DNA between mothers and newborns. HBsAg(+) and HBV DNA(+) rates of the infants at birth in
different levels of maternal HBsAg titer (A) and HBV DNA load (B) groups.
Figure 2 HBV DNA(+), HBsAg(+), HBeAg(+), anti-HBc(+), and anti-HBs(+) rates in infants. Positive rates of (A) HBV DNA, HBsAg, and HBeAg
and (B) anti-HBc and anti-HBs at birth, 1 mo, 7 mo and 12 mo.
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HBV infection; 32 in 37 infants with low levels of HBsAg
titer (from 0.05 IU/mL to 250 IU/mL) eliminated HBV
virus at the age of 12 months, other 5 infants with per-
sistently HBV DNA(+) and HBsAg(+), anti-HBs was
negative.
Anti-HBs(+) at 1 mo is an early indictor of HBV infection
Since neither HBV DNA(+) nor HBsAg(+) at birth can
be an indictor of HBV infection, a more sensitive and
specific indicator is needed for early predicting HBV in-
fection. Ours data demonstrated that all infants were di-
agnosed with HBV infection at 12 mo were anti-HBs(−)
at the 1 month (anti-HBs titers were from 0 mIU/mL to
2.94 mIU/mL). More important, 100% infants with anti-
HBs(+) at 1 mo were free of HBV infection at 12 mo
(Figure 4C), thus anti-HBs(+) at 1mo may be a reliable
early indictor for HBV infection. Further analysis
showed that the positive likelihood ratio of anti-HBs(−)
1mo was much higher than HBV DNA(+) and/or
HBsAg(+) (Table 3), suggesting a good indictor for early
HBV infection.
Discussion
The reported rates of HBV mother-infant infection in
China ranged from 3.2% to 40.1% [6-10,13,14]. Following
reasons were thought attributed to this significant vari-
ation: 1) the sample sizes of some studies were not large
enough, 2) since HBV DNA markers in newborns
change during the first year, follow-up should be last to
stable phase, and 3) the methods detecting HBV markers
were not sensitive enough. In current prospective, multi-
centers study, mothers screen HBsAg(+) and their new-
borns were enrolled and followed-up for as long as
12 months. More sensitive and specific tests were
employed to detect HBV DNA load and HBV markers
titer.
At birth, a substantial proportion of infants were de-
tected HBV markers positive, following 12 months follow-
up, we found that the positive rates of HBV DNA and
HBsAg gradually reduced. The rate of infants with HBsAg
(+) or HBV DNA(+) at birth resolved after 12 months
follow-up was as high as 81.3%, suggesting serum HBV
DNA(+) and HBsAg(+) at birth can not serve as the diag-
nostic markers for HBV infection. Although HBV DNA or
HBsAg is a widely used diagnostic marker for HBV infec-
tion in adults, for infants, both HBV DNA [14-16] and
HBsAg [16] may cross the human placenta via partial pla-
cental leakage or via the “cellular route”. In current study,
all the newborns were from HBV infected mother, which
ensured feasibility for infants to passively acquire HBV
markers from mothers. Secondly, if those markers de-
tected in infants passively pass form their mothers, infants
from highly replication mothers were more likely positive
for those markers. Supported by ours data, the infants
born to mothers with high levels of HBV DNA load or
high level of HBsAg were at greater risk of positivity for
HBV DNA or HBsAg at birth, when compared with those
infants of mothers with low level HBV DNA and HBsAg.
Thirdly, since those markers passively came from their
mothers, but not actively from HBV replication in infants’
liver, all those markers were fated to disappear eventually.
In our observation, HBsAg titer and HBV DNA load de-
creased gradually and eventually sero-converted to nega-
tivity in the non-infected infants. On the contrary, all
infected infants presented persistently HBV markers posi-
tive. All the infants with high HBV DNA load (>105 IU/
mL) and/or HBsAg titer (>250 IU/mL) at birth identified
HBV infection eventually. Although most of infants with
low levels of HBV DNA load (<105 IU/mL) and/or HBsAg
Table 2 Characteristics of the 9 mother–infant pairs
Mothers Infants






































(mIU/ml) (IU/ml) (s/co) (log10
IU/ml)
1 12462.2 1488.8 6.44 0.10 5.20 1.72 0.07 3.03 1.45 2.94 12340.14 894.68 6.72
2 >125000* 1969.5 8.34 9.93 20.44 8.12 >125000 1275.80 8.41 0 >125000 1516.68 8.53
3 83887.1 1540.9 7.49 9210.06 644.43 8.02 >125000 1236.10 8.08 0 >125000 1463.10 8.16
4 >125000 1898.8 7.03 0.08 19.95 7.68 0.08 3.25 8.54 0.02 >125000 1089.89 8.55
5 11359.4 0.6 4.64 1321.33 0.57 3.07 >125000 89.47 4.66 0 >125000 309.74 8.80
6 24560.1 1017.9 9.26 >125000 976.43 5.86 >125000 987.33 7.89 0 >125000 1167.23 8.90
7 19740.3 0.5 4.73 0.07 0.46 3.41 1675.44 0.72 4.53 0 1743.25 0.35 4.64
8 12049.5 0.7 3.43 0.72 0.57 1.95 2345.63 0.56 3.14 0.17 3142.317 0.59 3.63
9 >125000 1241.1 8.47 >125000 130.76 5.65 >125000 123.57 8.52 0.08 >125000* 790.13 8.56
>125000: The HBsAg titer exceeded the upper limit.
Chen et al. BMC Infectious Diseases 2013, 13:524 Page 5 of 8
http://www.biomedcentral.com/1471-2334/13/524
titer (<250 IU/mL) at birth were free of HBV at 12 months,
a small proportion of infants were persistent for HBV
DNA(+) and HBsAg(+) during the follow-up, which sup-
ported the notion that a sensitive detection methods, as
employed in our study, should be used for HBV infection
screening.
As shown above, both HBV DNA and HBsAg in in-
fants may be from their mothers. A non-mother-origin
marker is desperately needed for early diagnosis of HBV
infection. Although anti-HBs also pass through placenta
theoretically, all the mothers were anti-HBs(−). We
propose that anti-HBs probably serve as such marker.
Figure 3 Dynamic changes in HBV surface markers titer and HBV DNA load in infected and uninfected infants. Dynamic changes in HBV
DNA (A), HBsAg (B), HBeAg (C), anti-HBc (D), and anti-HBs (E) in infected and uninfected infants were compared at birth, 1 mo, 7 mo and 12 mo.
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Our data demonstrated that the infants with anti-HBs(+)
at 1 month, despite positivity for HBsAg or HBV DNA
at birth, were detected negative after 12 months follow-
up, whereas all the infants with anti-HBs(−) at 1 months
were identified as HBV infection. Additionally, the posi-
tive likelihood ratio of anti-HBs(−) at 1 month is the
highest among all the markers analyzed. Thus, negativity
for anti-HBs at 1 month can be considered as a sensitive
and early diagnostic indictor for HBV infection in infant
with HBV DNA(+) and HBsAg(+) at birth, especially for
those infants with low levels of HBV DNA load and
HBsAg titer.
Although revealed by this study that the anti-HBs(−)
at 1 month is sensitive and early indicator for HBV in-
fection, enlarged sample size is needed to confirm if this
indicator could be a diagnostic marker which can be ac-
ceptable used in clinic care.
Conclusions
This prospective, multi-centers study showed that the
HBV-infection rate of infants born to HBsAg-positive
mothers was 6.1% in Shaanxi Province, China. HBV
DNA(+) and HBsAg(+) at birth can not serve as the
diagnostic markers for HBV mother-infant infection.
Figure 4 Dynamic changes in HBV DNA load, HBsAg titer and anti-HBs titer in infants who were HBsAg(+) and HBV DNA(+) at birth.
Dynamic changes in HBV DNA load (A), HBsAg titer (B) and anti-HBs titer (C) in infants with HBsAg(+) and/or HBV DNA(+) at birth were compared
at birth, 1 mo, 7 mo and 12 mo.
Table 3 Positive likelihood ratio of diagnostic indicators for chronic HBV-infected infants
Diagnostic indicators N Infected Uninfected Positive
likelihood
ratio
N True positive ratio N False positive ratio
HBV DNA(+) at birth 21 9 9/9 = 1 12 12/139 = 0.086 11.6
HBsAg(+) at birth 41 9 9/9 = 1 32 32/139 = 0.230 4.34
HBV DNA- and HBsAg- positive at birth 18 9 9/9 = 1 9 9/139 = 0.065 15.4
Anti-HBs(−) at 1 month old 9 9 9/9 = 1 0 0/139 = 0 +∞
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Negativity for anti-HBs at 1 month can be considered as
a sensitive and early diagnostic indictor for HBV infec-
tion in infant with positive HBV DNA and HBsAg at
birth, especially for those infants with low levels of HBV
DNA load and HBsAg titer.
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